Cara lines up a $440M deal for US rights to its late-stage drug for severe itch, with $150M cash on the table
With plans afoot to file an NDA for what could be its first approved drug, Cara Therapeutics is pivoting its focus to commercialization. And Swiss company Vifor Pharma is willing to surrender up to $440 million to market the candidate in the US.
Cara $CARA CEO Derek Chalmers said an NDA submission is coming this quarter for their intravenous drug Korsuva in chronic kidney disease-associated pruritus (CKD-aP), a severe itching condition. The Stamford, CT-based biotech read out positive topline data from a Phase III pivotal study back in April, and announced plans to approach EMA regulators shortly after filing with the FDA.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,000+ biopharma pros reading Endpoints daily — and it's free.